Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Fulcrum Therapeutics from a "strong sell" to a "sell" rating, keeping the stock on the negative side of the street.
• Analyst coverage is mixed—seven Buy, one Hold and two Sell—resulting in a MarketBeat average rating of "Moderate Buy" and an average price target of $19.00.
• Shares trade around $7.37 with a market cap of about $491M, a negative P/E, institutional ownership near 89.8%, and the company recently beat quarterly EPS estimates (‑$0.25 vs. ‑$0.31).

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report issued on Saturday.

FULC has been the topic of a number of other research reports. Truist Financial set a $17.00 price objective on Fulcrum Therapeutics in a report on Tuesday, February 24th. Leerink Partners reissued an "outperform" rating on shares of Fulcrum Therapeutics in a report on Tuesday, February 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. initiated coverage on Fulcrum Therapeutics in a report on Monday, January 12th. They set an "overweight" rating and a $20.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $19.00.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $7.37 on Friday. The firm has a market cap of $490.73 million, a price-to-earnings ratio of -6.40 and a beta of 3.02. The business's 50-day simple moving average is $7.83 and its 200-day simple moving average is $9.50. Fulcrum Therapeutics has a 52 week low of $4.38 and a 52 week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Monday, April 27th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.06. As a group, equities research analysts forecast that Fulcrum Therapeutics will post -1.18 earnings per share for the current year.

Institutional Trading of Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its holdings in Fulcrum Therapeutics by 0.6% in the 4th quarter. Deutsche Bank AG now owns 287,096 shares of the company's stock valued at $3,247,000 after buying an additional 1,767 shares during the last quarter. Intech Investment Management LLC grew its holdings in Fulcrum Therapeutics by 14.5% in the 4th quarter. Intech Investment Management LLC now owns 19,747 shares of the company's stock valued at $223,000 after buying an additional 2,503 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at approximately $30,000. Strs Ohio grew its holdings in Fulcrum Therapeutics by 3.7% in the 3rd quarter. Strs Ohio now owns 77,900 shares of the company's stock valued at $717,000 after buying an additional 2,800 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at approximately $39,000. Institutional investors and hedge funds own 89.83% of the company's stock.

Trending Headlines about Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS forecasts, narrowing expected losses for 2026 — the analyst (A. Maldonado) bumped Q2, Q3 and Q4 2026 EPS slightly (e.g., Q2 to ($0.26), Q3/Q4 to ($0.27)) and lifted FY2026 to ($1.05) from ($1.12). That reduction in expected losses improves short‑term fundamentals and likely helped buying interest. MarketBeat FULC Analyst Note
• Neutral Sentiment: The Globe and Mail ran a sector roundup noting analyst commentary on several healthcare names including Fulcrum; the piece is a general market/analyst overview rather than a company‑specific operational update, so it is unlikely to be a standalone catalyst. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright substantially lowered longer‑term earnings power: FY2028 EPS was cut from $0.87 to $0.39, FY2029 from $1.79 to $0.83 and FY2030 from $2.71 to $1.68. Those downward revisions reduce modeled long‑term upside and increase uncertainty about the company’s path to sustained profitability. MarketBeat FULC Analyst Note

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.